Login to Your Account



Paradigm Therapeutics Gets £12M On Strength Of Murine Program

By Nuala Moran


Wednesday, December 11, 2002
Sequencing the mouse genome is unlikely to provoke a fund-raising spate like that which flowed from the publication of its human counterpart, but Paradigm Therapeutics Ltd. was keen to stress its murine credentials this week when it announced the completion of a £12 million (US$19 million) second-round funding. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription